NASDAQ:BCTXW BriaCell Therapeutics (BCTXW) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free BCTXW Stock Alerts $0.59 +0.04 (+7.26%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$0.51▼$0.6250-Day Range$0.55▼$1.5452-Week Range$0.51▼$3.30Volume27,771 shsAverage Volume29,332 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get BriaCell Therapeutics alerts: Email Address Ad Banyan Hill PublishingCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. About BriaCell Therapeutics Stock (NASDAQ:BCTXW)BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Read More BCTXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCTXW Stock News HeadlinesMay 16 at 6:21 PM | uk.investing.comBriacell Therapeutics Corp (BCTX)February 20, 2024 | finance.yahoo.comGet Rich Quick With These 3 Penny Stocks to Buy NowFebruary 7, 2024 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder CaseFebruary 6, 2024 | finance.yahoo.comBreaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP ManufacturingJanuary 6, 2024 | theglobeandmail.comBriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)January 4, 2024 | finance.yahoo.comBriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast CancerDecember 6, 2023 | finance.yahoo.comBriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical BenefitNovember 30, 2023 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell Records New Responder with Remarkable Improvement of "Eye-Bulging" Metastatic TumorNovember 30, 2023 | finance.yahoo.comBriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic TumorOctober 18, 2023 | finance.yahoo.comBriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) ConferencesOctober 4, 2023 | finance.yahoo.comBriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast CancerAugust 25, 2023 | finance.yahoo.comBriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics (SpinCo) to Existing ShareholdersMay 25, 2023 | finance.yahoo.comBriaCell Enters Definitive Arrangement Agreement for the Spin Out of BriaPro Therapeutics Corp.April 17, 2023 | finance.yahoo.comBriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACRApril 3, 2023 | bizjournals.comBriaCell intends to launch a spinoff to accelerate its drug development activitiesMarch 15, 2023 | finance.yahoo.comBriaCell to Present Clinical and Survival Data in Advanced Metastatic Breast Cancer at the 2023 AACR Annual MeetingJanuary 23, 2023 | finanznachrichten.deBriaCell Therapeutics Corp.: BriaCell to Investigate Alleged Illegal Trading of Public SecuritiesJanuary 10, 2023 | finance.yahoo.comBriaCell Announces New Patent Issuance, Bria-OTS™ IND Timing Guidance, and Additional Clinical Sites to Boost EnrolmentDecember 8, 2022 | finance.yahoo.comBriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®October 21, 2022 | finance.yahoo.comBriaCell Announces Successful Completion of Phase I Portion of Clinical Study in Advanced Breast Cancer; Randomized Phase II Efficacy Evaluation ProgressingAugust 4, 2022 | finance.yahoo.comBriaCell Secures License for a Promising Novel Anti-Cancer AgentJune 29, 2022 | finance.yahoo.comBriaCell Enters Research Agreement to Identify Novel Targets for Cancer TreatmentSee More Headlines Receive BCTXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BCTXW CUSIPN/A CIK1610820 WebN/A Phone604-921-1810FaxN/AEmployees16Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. William V. Williams M.D. (Age 69)CEO, President & Director Comp: $785.3kMr. Gadi Levin B.Com. (Age 51)C.A., CPA, M.B.A., CFO & Corporate Secretary Comp: $304.46kDr. Miguel A. Lopez-Lago Ph.D. (Age 55)Chief Scientific Officer Comp: $298.9kDr. Giuseppe Del Priore M.D. (Age 62)M.P.H., MPH, Chief Medical Officer Comp: $492.5kDr. Charles Louis Wiseman FACP (Age 78)M.D., Founder, Principal Research Advisor & Member of Scientific Advisory Board Comp: $241.14kKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors BCTXW Stock Analysis - Frequently Asked Questions How have BCTXW shares performed in 2024? BriaCell Therapeutics' stock was trading at $2.50 at the start of the year. Since then, BCTXW shares have decreased by 76.4% and is now trading at $0.5906. View the best growth stocks for 2024 here. How do I buy shares of BriaCell Therapeutics? Shares of BCTXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BCTXW) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceI’m afraid WWIII is a very real possibility Porter & CompanyProtect Your Bank Account Before It’s Too LateWeiss RatingsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
